LY2886721 structure
|
Common Name | LY2886721 | ||
---|---|---|---|---|
CAS Number | 1262036-50-9 | Molecular Weight | 390.407 | |
Density | 1.6±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C18H16F2N4O2S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of LY2886721LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease.IC50 value:Target: BACELY2886721 is a novel potent agent that is used to treat Alzheimer’s Disease in preclinical experiments. LY2886721 is under clinical study. A Safety Study of LY2886721 Multiple Doses is performing in Healthy Subjects. |
Name | N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide |
---|---|
Synonym | More Synonyms |
Description | LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease.IC50 value:Target: BACELY2886721 is a novel potent agent that is used to treat Alzheimer’s Disease in preclinical experiments. LY2886721 is under clinical study. A Safety Study of LY2886721 Multiple Doses is performing in Healthy Subjects. |
---|---|
Related Catalog | |
References |
[1]. A Safety Study of LY2886721 Multiple Doses in Healthy Subjects |
Density | 1.6±0.1 g/cm3 |
---|---|
Molecular Formula | C18H16F2N4O2S |
Molecular Weight | 390.407 |
Exact Mass | 390.096191 |
PSA | 112.40000 |
LogP | 0.80 |
Index of Refraction | 1.706 |
Storage condition | -20°C |
Hazard Codes | Xi |
---|
~99% LY2886721 CAS#:1262036-50-9 |
Literature: US2011/9395 A1, ; Page/Page column 12 ; |
~% LY2886721 CAS#:1262036-50-9 |
Literature: US2011/9395 A1, ; Page/Page column 33 ; |
Precursor 2 | |
---|---|
DownStream 1 | |
LY-2886721 |
cc-426 |
S2156_Selleck |
UNII:2CQ62IWB67 |
LY2886721 |
UNII-2CQ62IWB67 |
LY 2886721 |